Cancers figure among the leading causes of morbidity and mortality worldwide. Treatments for cancer controlling lack of selectivity towards cancer cells leading to a wide spectrum of severe side-effects, in part due to the little or no selectivity of drugs for cancer cells over healthy cells. We are committed to develop new metallodrugs that might lead to different mechanisms of action with improved selectivity.
Targeting metastatic breast cancer
Breast cancer is the leading cause of cancer death in women worldwide. Although many BC can be successfully treated when early detected, high aggressive and metastatic breast cancer, unresponsive to hormonal therapies has higher recurrence and lower survival rates due to the lack of efficient and specific therapies. Most treatments for cancer controlling present low therapeutic indices and a wide spectrum of severe side-effects, in part due to the little or no selectivity of drugs for cancer cells over non-tumoral cells. To overcome this limitation, we are developing new ruthenium-peptide conjugates based on ruthenium organometallic complexes conjugated to peptides that bind selectively to receptors overexpressed at the cancer cell surfaces in order to selective delivery of ruthenium drugs to cancer cells.
Copper complexes for cancer Therapy
We are committed to develop new copper(I) complexes for cancer therapy and understand whether/how structural factors affect the biological properties of the complexes.